Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574663 | 0.93 | OGA (0.43) | SIGMAR1OGAHTTSMN1; SMN2CHRM4 | |
| SCHEMBL3406346 | 0.78 | MAPT (0.46) | SIGMAR1HRH3CCR5CXCR4TRPV6 | |
| SCHEMBL5850284 | 0.72 | CCR5 (0.43) | SIGMAR1HRH3CCR5CXCR4CYP1A2 | |
| SCHEMBL5672613 | 0.70 | ACHE (0.54) | ACHE | |
| SCHEMBL5671758 | 0.70 | KDM1A (0.49) | SMN1; SMN2ACHE | |
| SCHEMBL2768950 | 0.69 | FKBP1A (0.54) | CYP3A4GBA1 | |
| SCHEMBL9233648 | 0.69 | KDM4E (0.45) | SMN1; SMN2 | |
| SCHEMBL8844231 | 0.68 | TRPV6 (0.57) | SIGMAR1HRH3CCR5CXCR4CYP1A2 | |
| SCHEMBL6574223 | 0.68 | MAPT (0.45) | OGAHTTSMN1; SMN2HRH3 | |
| SCHEMBL11237070 | 0.68 | SLC18A3 (0.42) | SIGMAR1OGASMN1; SMN2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | SIGMAR1 1349/4885OGA 1827/4885HTT 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.